In Treatment

Research into small cell lung cancer may soon pay off in new treatments. Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute discusses new approaches that hold great promise. February 2014

[powerpress]

HER2 inhibitors have been successfully used to combat breast cancer, but research has shown that a small percentage of lung cancer patients have a HER2 mutation as well. Dr. Leena Gandhi talks about the role that HER2 drugs may play to fight lung cancer.

[powerpress]

Leptomeningeal carcinomatosis is cancer that has spread to the coating of the brain and spinal cord. In the past, prognosis has been bad. But now doctors are learning of effective treatments to deal with this issue.

[powerpress]

The Northwest Medical Development Therapeutics Institute is breaking new ground by conducting clinical trials that will test treatments based on tumor mutations, rather than where the tumor began. Dr. Melissa Johnson describes the work of the center.

[powerpress]

Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes how he helps his EGFR lung cancer patients make decisions about next steps in treatment when their cancers grow.

[powerpress]

Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks about what they are learning in this area.

[powerpress]

"HSP 90 inhibitors are a really cool class of drugs..." states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she describes what researchers are learning about these drugs still in early development. February 2014.

[powerpress]

Dr. Leena Gandhi of Dana-Farber Cancer Institute sees great potential in immune therapies for lung cancer. In this video, she expresses her hope and excitement for what the future may hold. February 2014.

[powerpress]

A genetic mutation and a leukemia drug may provide new hope for patients with squamous cell lung cancer patients.

[powerpress]

The following piece is from the University of Colorado, where Dr. Camidge and some others there are leading a very novel trial for a small molecularly defined subgroup with specific biomarkers related to fibroblast growth factor receptor-1 (FGFR1) are potential candidates for a trial just launching now with the agent ponatinib, a tyrosine kinase inhibitor (TKI) that hits many targets.